Your browser is no longer supported. Please, upgrade your browser.
Coherus BioSciences, Inc.
Index- P/E- EPS (ttm)-3.13 Insider Own1.10% Shs Outstand79.01M Perf Week-9.83%
Market Cap889.84M Forward P/E- EPS next Y-0.92 Insider Trans-33.92% Shs Float67.42M Perf Month-33.78%
Income-231.70M PEG- EPS next Q-0.44 Inst Own- Short Float10.56% Perf Quarter-28.62%
Sales363.60M P/S2.45 EPS this Y32.30% Inst Trans-0.08% Short Ratio9.60 Perf Half Y-12.71%
Book/sh1.65 P/B6.95 EPS next Y20.00% ROA-30.70% Target Price25.43 Perf Year-40.88%
Cash/sh6.04 P/C1.90 EPS next 5Y- ROE-133.20% 52W Range11.92 - 22.22 Perf YTD-28.13%
Dividend- P/FCF19.26 EPS past 5Y17.80% ROI22.30% 52W High-48.37% Beta0.99
Dividend %- Quick Ratio2.00 Sales past 5Y73.80% Gross Margin84.30% 52W Low-3.78% ATR0.68
Employees334 Current Ratio2.10 Sales Q/Q-27.40% Oper. Margin-57.20% RSI (14)16.89 Volatility5.86% 4.86%
OptionableYes Debt/Eq3.11 EPS Q/Q-246.50% Profit Margin-63.70% Rel Volume1.64 Prev Close12.04
ShortableYes LT Debt/Eq2.16 EarningsNov 08 AMC Payout- Avg Volume741.53K Price11.47
Recom2.10 SMA20-19.87% SMA50-30.18% SMA200-25.35% Volume1,215,577 Change-4.73%
Jul-16-20Initiated BofA Securities Neutral $20
Apr-17-20Initiated SunTrust Buy $26
Aug-13-19Initiated Mizuho Buy
Aug-02-19Reiterated Maxim Group Buy $25 → $27
Aug-02-19Reiterated H.C. Wainwright Buy $28 → $29
Jun-11-19Initiated Barclays Overweight $30
May-07-19Initiated H.C. Wainwright Buy $28
Aug-28-18Initiated H.C. Wainwright Buy $28
Mar-09-18Reiterated Maxim Group Buy $20 → $15
Aug-08-17Reiterated JP Morgan Overweight $32 → $25
Jun-13-17Reiterated Maxim Group Buy $44 → $40
May-05-17Initiated BMO Capital Markets Outperform $54
Oct-19-16Initiated Robert W. Baird Outperform $40
Sep-07-16Initiated Maxim Group Buy $43
Jul-27-16Initiated Citigroup Buy $36
Jan-20-16Initiated Credit Suisse Outperform
Jan-10-22 07:30AM  
Jan-07-22 08:30AM  
Jan-04-22 08:32AM  
Dec-20-21 07:59AM  
Dec-17-21 09:09AM  
Dec-16-21 04:30PM  
Dec-15-21 09:08PM  
Dec-13-21 07:00AM  
Nov-18-21 06:45PM  
Nov-16-21 09:08AM  
Nov-15-21 08:30AM  
Nov-11-21 05:46AM  
Nov-10-21 04:15PM  
Nov-08-21 10:00PM  
Nov-05-21 08:30AM  
Nov-01-21 07:30AM  
Oct-29-21 04:12PM  
Oct-28-21 03:05PM  
Oct-11-21 08:30AM  
Oct-05-21 12:52PM  
Oct-04-21 08:00AM  
Oct-01-21 01:09PM  
Sep-30-21 11:11AM  
Sep-29-21 04:30PM  
Sep-28-21 10:11AM  
Sep-24-21 04:15PM  
Sep-17-21 07:39AM  
Sep-16-21 06:28PM  
Sep-15-21 08:30AM  
Sep-13-21 08:55PM  
Sep-10-21 08:45AM  
Sep-08-21 08:30AM  
Sep-01-21 08:01AM  
Aug-25-21 10:08AM  
Aug-19-21 11:54AM  
Aug-18-21 09:09PM  
Aug-17-21 09:05AM  
Aug-12-21 08:01AM  
Aug-06-21 10:31AM  
Aug-05-21 05:35PM  
Jul-29-21 03:04PM  
Jul-26-21 04:31PM  
Jul-21-21 09:15AM  
Jul-19-21 06:39PM  
Jul-12-21 08:29PM  
Jun-07-21 09:35AM  
Jun-04-21 04:01PM  
Jun-03-21 08:46PM  
May-25-21 08:26PM  
May-15-21 03:39AM  
May-07-21 04:01PM  
May-06-21 10:31PM  
Apr-30-21 04:15PM  
Apr-29-21 05:03PM  
Apr-23-21 08:00AM  
Apr-20-21 08:00AM  
Mar-23-21 02:09AM  
Mar-03-21 06:45AM  
Feb-27-21 06:15AM  
Feb-25-21 08:45AM  
Feb-24-21 04:01PM  
Feb-18-21 08:30AM  
Feb-17-21 07:30AM  
Feb-16-21 08:00AM  
Feb-14-21 01:32PM  
Feb-06-21 02:24AM  
Feb-02-21 08:30AM  
Feb-01-21 07:53AM  
Jan-22-21 04:01PM  
Jan-07-21 04:01PM  
Jan-05-21 04:01PM  
Dec-21-20 04:02PM  
Nov-20-20 04:01PM  
Nov-09-20 09:30AM  
Nov-07-20 08:22AM  
Nov-06-20 03:30PM  
Nov-05-20 05:35PM  
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stilwell McDavidChief Financial OfficerOct 15Sale16.803,50758,91931,611Oct 19 07:36 PM
HEALY JAMESDirectorSep 29Sale16.12286,0764,611,5450Sep 29 08:18 PM
HEALY JAMESDirectorSep 28Sale17.1748,329829,809286,076Sep 29 08:18 PM
HEALY JAMESDirectorSep 27Sale18.06100,1501,808,709334,405Sep 29 08:18 PM
Stilwell McDavidChief Financial OfficerJun 09Buy13.423,70049,66835,118Jun 10 04:35 PM
Lanfear Dennis MPresident & CEOJun 08Option Exercise0.4231,05412,943524,312Jun 08 05:11 PM
Lanfear Dennis MPresident & CEOJun 08Sale13.5631,054421,229493,258Jun 08 05:11 PM
Lanfear Dennis MPresident & CEOJun 06Option Exercise0.42300,000125,040493,258Jun 08 05:11 PM
Vexler VladimirChief Scientific OfficerMar 09Option Exercise8.01102,480820,665167,626Mar 11 05:37 PM
Vexler VladimirChief Scientific OfficerMar 09Sale16.25114,2401,856,26353,386Mar 11 05:37 PM
Anicetti Vincent RChief Operating OfficerMar 05Option Exercise9.3020,312188,90280,051Mar 09 04:24 PM
Anicetti Vincent RChief Operating OfficerMar 05Sale15.4626,649412,06553,402Mar 09 04:24 PM
Anicetti Vincent RChief Operating OfficerFeb 17Option Exercise2.502,4886,22162,227Feb 19 04:11 PM
Anicetti Vincent RChief Operating OfficerFeb 17Sale17.452,48843,41859,739Feb 19 04:11 PM
Viret Jean-FredericChief Financial OfficerFeb 01Option Exercise10.057,40274,39068,697Feb 03 05:37 PM
Viret Jean-FredericChief Financial OfficerFeb 01Sale21.557,402159,51361,295Feb 03 05:37 PM